



US006166017A

**United States Patent** [19]  
**Marin****[11] Patent Number: 6,166,017**  
**[45] Date of Patent: \*Dec. 26, 2000**

[54] **METHOD OF USING KETOCONAZOLE AND RELATED SUBSTANCES IN MEDICAMENTS FOR TREATMENT OF TYPE II DIABETES AND METHODS OF TREATING SAME**

[75] Inventor: **Per Marin**, Göteborg, Sweden

[73] Assignee: **Cortendo, AB**, Gothenburg, Sweden

[\*] Notice: This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

This patent is subject to a terminal disclaimer.

[21] Appl. No.: **09/211,282**

[22] Filed: **Dec. 14, 1998**

**Related U.S. Application Data**

[63] Continuation of application No. 08/776,983, filed as application No. PCT/SE94/00729, Aug. 9, 1994, Pat. No. 5,849,740.

[51] **Int. Cl.**<sup>7</sup> ..... **A61K 31/50**; A61K 31/56; A61K 31/415; A61K 31/335

[52] **U.S. Cl.** ..... **514/247**; 514/178; 514/396; 514/467; 514/866

[58] **Field of Search** ..... 514/247, 178, 514/396, 467, 866

**[56] References Cited****U.S. PATENT DOCUMENTS**

|           |         |        |       |         |
|-----------|---------|--------|-------|---------|
| 5,175,144 | 12/1992 | Walser | ..... | 514/2   |
| 5,432,176 | 7/1995  | Walser | ..... | 514/252 |
| 5,591,736 | 1/1997  | Walser | ..... | 514/178 |
| 5,849,740 | 12/1998 | Marin  | ..... | 514/247 |

**OTHER PUBLICATIONS**

Viscera Obesity; A "Civilization Syndrome". Obesity Research, vol. 1 No. 3, May 1993.

A.T. Sapse, "Stress, Cortisol, Intreferon and 'Stress' Diseases —I. Cortisol as the Cause of 'Stress' Diseases", Medical Hypotheses, vol. 13 pp. 31–44, 1984.

*Primary Examiner*—Kevin E. Weddington

*Attorney, Agent, or Firm*—Hopgood, Calimafde, Judlowe & Mondolino

**[57] ABSTRACT**

A method for the medical treatment of diabetes mellitus type II and for counteracting the risk factors forming part of the Metabolic syndrome (also known as the "deadly quartet" or "syndrome X" or the Insulin Resistance Syndrome) in a patient having increased cortisol activity, which method of treatment comprises decreasing said increased cortisol activity in said patient by the steps of providing an inhibitor of cortisol synthesis.

**19 Claims, No Drawings**